Four new grantees received the Catalyst Awards for Innovative Research Approaches for AMD.
RPB and AUPO announce the 2018 recipient of the award focused on age-related macular degeneration.
RPB-supported researchers at the University of Southern California Roski Eye Institute conducted the human trial.
RPB-supported researchers made a critical discovery about the gene mutation that causes many retinal degenerative diseases, opening the door for a new line of research into potential treatments.
The model will allow researchers to better assess treatments for this hard-to-study cause of blindness.
The findings may have significant therapeutic implications for AMD, the most common cause of elderly blindness in the developed world
At the ARVO Inaugural Press Conference, three RPB-funded scientists pushing the boundaries of imaging, early detection, regeneration.
Adults whose eyes are slow to adjust to the dark have a greater risk of developing age-related macular degeneration.
Some patients taking high doses of a cholesterol-lowering medication had complete resolution of lipid deposits in the dry form of age-related macular degeneration (AMD).
RPB-supported researchers have made a significant discovery that might lead to the delay or prevention of the most common cause of blindness in the elderly.